Suven Life Sciences Limited (SUVEN.NS)
INR 142.78
(-0.61%)
INR 142.78
(-0.61%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.22 Billion INR | -1.96% |
| 2022 | -1.31 Billion INR | -4.52% |
| 2021 | -1.26 Billion INR | -51.55% |
| 2020 | -832.84 Million INR | 30.29% |
| 2019 | -1.19 Billion INR | -186.21% |
| 2018 | 1.38 Billion INR | -21.78% |
| 2017 | 1.77 Billion INR | 73.89% |
| 2016 | 1.01 Billion INR | 21.75% |
| 2015 | 836.83 Million INR | -43.39% |
| 2014 | 1.47 Billion INR | -29.68% |
| 2013 | 2.1 Billion INR | 363.88% |
| 2012 | 453.18 Million INR | 137.88% |
| 2011 | 190.51 Million INR | 97.18% |
| 2010 | 96.61 Million INR | 7.86% |
| 2009 | 89.57 Million INR | -51.28% |
| 2008 | 183.84 Million INR | 121.2% |
| 2007 | 83.11 Million INR | -32.77% |
| 2006 | 123.61 Million INR | 68.58% |
| 2005 | 73.32 Million INR | 31.74% |
| 2004 | 55.66 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -536.63 Million INR | -67.57% |
| 2024 Q1 | -320.24 Million INR | -0.72% |
| 2023 Q2 | -200.94 Million INR | 32.29% |
| 2023 Q4 | -317.96 Million INR | 23.8% |
| 2023 Q3 | -417.29 Million INR | -107.66% |
| 2023 Q1 | -296.78 Million INR | -7.57% |
| 2023 FY | -1.34 Billion INR | -1.96% |
| 2022 Q3 | -510.51 Million INR | -120.89% |
| 2022 Q1 | -226.6 Million INR | -8.85% |
| 2022 FY | -1.31 Billion INR | -4.52% |
| 2022 Q2 | -231.12 Million INR | -1.99% |
| 2022 Q4 | -275.9 Million INR | 45.95% |
| 2021 Q3 | -337.01 Million INR | -17.63% |
| 2021 Q4 | -208.18 Million INR | 38.23% |
| 2021 FY | -1.26 Billion INR | -51.55% |
| 2021 Q1 | -436.1 Million INR | -102.96% |
| 2021 Q2 | -286.51 Million INR | 34.3% |
| 2020 Q3 | -277.48 Million INR | -48.65% |
| 2020 Q2 | -186.67 Million INR | -22.32% |
| 2020 Q1 | -152.61 Million INR | 40.41% |
| 2020 FY | -832.84 Million INR | 30.29% |
| 2020 Q4 | -214.87 Million INR | 22.56% |
| 2019 Q3 | -285.24 Million INR | -129.6% |
| 2019 Q2 | 963.63 Million INR | 78.8% |
| 2019 FY | -1.19 Billion INR | -186.21% |
| 2019 Q1 | 538.93 Million INR | -53.04% |
| 2019 Q4 | -256.09 Million INR | 10.22% |
| 2018 Q2 | 47.13 Million INR | -88.19% |
| 2018 FY | 1.38 Billion INR | -21.78% |
| 2018 Q4 | 1.14 Billion INR | 652.97% |
| 2018 Q3 | -207.52 Million INR | -540.26% |
| 2018 Q1 | 399.07 Million INR | 0.0% |
| 2017 FY | 1.77 Billion INR | 73.89% |
| 2016 Q4 | 856.75 Million INR | 0.0% |
| 2016 FY | 1.01 Billion INR | 21.75% |
| 2015 FY | 836.83 Million INR | -43.39% |
| 2015 Q2 | 320.22 Million INR | 17.69% |
| 2015 Q3 | 240.85 Million INR | -24.78% |
| 2015 Q1 | 272.09 Million INR | 371.9% |
| 2015 Q4 | 818.91 Million INR | 240.0% |
| 2014 FY | 1.47 Billion INR | -29.68% |
| 2014 Q1 | 565.72 Million INR | 30.55% |
| 2014 Q4 | 57.66 Million INR | -88.03% |
| 2014 Q3 | 481.51 Million INR | 28.99% |
| 2014 Q2 | 373.28 Million INR | -34.02% |
| 2013 Q2 | 693.07 Million INR | 57.19% |
| 2013 Q1 | 440.92 Million INR | 312.59% |
| 2013 Q3 | 534.86 Million INR | -22.83% |
| 2013 Q4 | 433.35 Million INR | -18.98% |
| 2013 FY | 2.1 Billion INR | 363.88% |
| 2012 Q2 | 61.54 Million INR | -57.67% |
| 2012 Q3 | 139.38 Million INR | 126.49% |
| 2012 Q4 | 106.86 Million INR | -23.33% |
| 2012 FY | 453.18 Million INR | 137.88% |
| 2012 Q1 | 145.39 Million INR | 0.0% |
| 2011 FY | 190.51 Million INR | 97.18% |
| 2010 FY | 96.61 Million INR | 7.86% |
| 2009 FY | 89.57 Million INR | -51.28% |
| 2008 FY | 183.84 Million INR | 121.2% |
| 2007 FY | 83.11 Million INR | -32.77% |
| 2006 FY | 123.61 Million INR | 68.58% |
| 2005 FY | 73.32 Million INR | 31.74% |
| 2004 FY | 55.66 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Sigachi Industries Limited | 1.47 Billion INR | 183.169% |
| Ind-Swift Limited | 1.22 Billion INR | 199.988% |
| Bajaj HealthCare Limited | - INR | Infinity% |
| Sakar Healthcare Limited | 495.5 Million INR | 347.388% |
| Aurobindo Pharma Limited | 104.5 Billion INR | 101.173% |
| Innova Captab Limited | 2.53 Billion INR | 148.386% |
| Divi's Laboratories Limited | 18.31 Billion INR | 106.695% |
| AstraZeneca Pharma India Limited | 4.47 Billion INR | 127.399% |
| Morepen Laboratories Limited | 4.17 Billion INR | 129.369% |
| Mankind Pharma Limited | 40.86 Billion INR | 102.999% |
| Sequent Scientific Limited | - INR | Infinity% |
| Wanbury Limited | 1.7 Billion INR | 171.803% |
| Laurus Labs Limited | 3.94 Billion INR | 131.044% |
| Nectar Lifesciences Limited | 3.89 Billion INR | 131.507% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 113.652% |
| Alembic Limited | 767.77 Million INR | 259.66% |
| Hikal Limited | 1.49 Billion INR | 182.039% |
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 121.289% |
| Neuland Laboratories Limited | 5.31 Billion INR | 123.05% |
| J. B. Chemicals & Pharmaceuticals Limited | 7.54 Billion INR | 116.254% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 118.852% |
| IOL Chemicals and Pharmaceuticals Limited | 4.94 Billion INR | 124.803% |
| Themis Medicare Limited | 1.3 Billion INR | 194.069% |
| RPG Life Sciences Limited | 2.29 Billion INR | 153.476% |
| Zydus Lifesciences Limited | 45.39 Billion INR | 102.701% |
| Lupin Limited | 27.75 Billion INR | 104.416% |
| Amrutanjan Health Care Limited | 621.02 Million INR | 297.386% |
| Wockhardt Limited | 140 Million INR | 975.587% |
| Vaishali Pharma Limited | 6.29 Million INR | 19576.041% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 139.187% |
| Jagsonpal Pharmaceuticals Limited | 214.04 Million INR | 672.707% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 123.623% |
| FDC Limited | 3.03 Billion INR | 140.406% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 101.81% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | 689.196% |
| Eris Lifesciences Limited | 5.18 Billion INR | 123.657% |
| Venus Remedies Limited | 534.65 Million INR | 329.275% |
| ZIM Laboratories Limited | 1.09 Billion INR | 211.63% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | 199.579% |
| Par Drugs and Chemicals Limited | 551.58 Million INR | 322.235% |
| Caplin Point Laboratories Limited | 7.22 Billion INR | 116.966% |
| Shilpa Medicare Limited | 3.76 Billion INR | 132.588% |
| Albert David Limited | 1.33 Billion INR | 191.859% |
| Ajanta Pharma Limited | 19.67 Billion INR | 106.23% |
| Hester Biosciences Limited | 364.77 Million INR | 436.053% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 126.604% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 68.184% |
| Gufic Biosciences Limited | 2.89 Billion INR | 142.36% |
| Windlas Biotech Limited | 1.29 Billion INR | 194.375% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 143.999% |
| Aarey Drugs & Pharmaceuticals Limited | 2.83 Million INR | 43402.626% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | 4564.353% |
| Granules India Limited | 6.52 Billion INR | 118.777% |
| Aarti Drugs Limited | 7.14 Billion INR | 117.147% |
| Bal Pharma Limited | 214.56 Million INR | 671.295% |
| Alkem Laboratories Limited | 19.46 Billion INR | 106.299% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 101.175% |
| Lincoln Pharmaceuticals Limited | 1.9 Billion INR | 164.303% |
| Medicamen Biotech Limited | - INR | Infinity% |
| Unichem Laboratories Limited | - INR | Infinity% |
| Bafna Pharmaceuticals Limited | 237.66 Million INR | 615.786% |
| Biofil Chemicals and Pharmaceuticals Limited | 20.65 Million INR | 6034.46% |
| Valiant Laboratories Limited | - INR | Infinity% |
| Orchid Pharma Limited | 2.36 Billion INR | 151.918% |
| Medico Remedies Limited | 277.11 Million INR | 542.347% |
| Ind-Swift Laboratories Limited | 2 Billion INR | 161.016% |
| Ipca Laboratories Limited | 29.59 Billion INR | 104.142% |
| Brooks Laboratories Limited | -72.25 Million INR | -1596.592% |
| Syncom Formulations (India) Limited | 249.25 Million INR | 591.802% |
| Piramal Enterprises Limited | - INR | Infinity% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 104.838% |
| NATCO Pharma Limited | 25.96 Billion INR | 104.722% |
| Krebs Biochemicals & Industries Limited | - INR | Infinity% |
| Strides Pharma Science Limited | 5.22 Billion INR | 123.457% |
| Indoco Remedies Limited | 1.52 Billion INR | 180.413% |
| Alpa Laboratories Limited | 61.51 Million INR | 2092.72% |
| Lasa Supergenerics Limited | -458 Million INR | -167.644% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 70.211% |